• Publications
  • Influence
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response
BACKGROUND Interleukin-5 (IL-5) is essential for the formation of eosinophils, which are thought to have a major role in the pathogenesis of asthma and other allergic diseases. We aimed to assess theExpand
  • 1,752
  • 33
European Position Paper on Rhinosinusitis and Nasal Polyps 2020.
The European Position Paper on Rhinosinusitis and Nasal Polyps 2020 is the update of similar evidence based position papers published in 2005 and 2007 and 2012. The core objective of the EPOS2020Expand
  • 404
  • 10
  • PDF
Biomarkers in asthma and allergic rhinitis.
A biological marker (biomarker) is a physical sign or laboratory measurement that can serve as an indicator of biological or pathophysiological processes or as a response to a therapeuticExpand
  • 52
  • 8
The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo.
BACKGROUND The 5-lipoxygenase metabolites of arachidonic acid are likely to be involved in the pathophysiology of atopic asthma. We investigated the effect of pretreatment with MK-0591, a novelExpand
  • 145
  • 5
Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
BACKGROUND Many patients with asthma or chronic obstructive pulmonary disease (COPD) routinely receive a combination of an inhaled bronchodilator and anti-inflammatory glucocorticosteroid, but thoseExpand
  • 94
  • 5
ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests
This international task force report updates general considerations for bronchial challenge testing and the performance of the methacholine challenge test. There are notable changes from priorExpand
  • 84
  • 5
Montelukast in the treatment of asthma and beyond
Asthma is a chronic inflammatory disease affecting over 300 million people worldwide. The common association with allergic rhinitis and the presence of proinflammatory cells and mediators in theExpand
  • 45
  • 5
PDE4-inhibitors: a novel, targeted therapy for obstructive airways disease.
Roflumilast is a selective once daily, oral phosphodiesterase-4 inhibitor that has recently been registered in all European Union countries as novel targeted therapy for COPD, while FDA approval forExpand
  • 45
  • 4
Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma.
Heparin possesses anti-inflammatory properties, which appeared to be dependent on the dose, timing, and the route of administration in animal studies. In asthma, a single dose of inhaled heparin onlyExpand
  • 128
  • 3
Lung sounds during allergen-induced asthmatic responses in patients with asthma.
We postulated that the distinct pathophysiologic mechanisms of airway narrowing during the early (EAR) and the late (LAR) asthmatic responses to inhaled allergens are reflected by the generation orExpand
  • 30
  • 3